Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Catabasis Pharmaceuticals stock | $7.29

Learn how to easily invest in Catabasis Pharmaceuticals stock.

Catabasis Pharmaceuticals Inc is a biotechnology business based in the US. Catabasis Pharmaceuticals shares (CATB) are listed on the NASDAQ and all prices are listed in US Dollars. Catabasis Pharmaceuticals employs 20 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Catabasis Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CATB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Catabasis Pharmaceuticals stock price (NASDAQ: CATB)

Use our graph to track the performance of CATB stocks over time.

Catabasis Pharmaceuticals shares at a glance

Information last updated 2021-10-09.
Latest market close$7.29
52-week range$6.31 - $38.76
50-day moving average $8.23
200-day moving average $3.74
Wall St. target price$23.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-54.39

Buy Catabasis Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Catabasis Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Catabasis Pharmaceuticals price performance over time

Historical closes compared with the close of $7.29 from 2021-10-14

1 week (2021-10-07) -1.75%
1 month (2021-09-16) -26.66%
3 months (2021-07-16) 341.82%
6 months (2021-04-15) 207.59%
1 year (2020-10-15) 17.20%
2 years (2019-10-15) 51.88%
3 years (2018-10-15) 978.40%
5 years (2016-10-14) 49.69%

Catabasis Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -20.32%
Return on equity TTM -210.26%
Profit margin 0%
Book value $2.90
Market capitalisation $109.5 million

TTM: trailing 12 months

Shorting Catabasis Pharmaceuticals shares

There are currently 578,303 Catabasis Pharmaceuticals shares held short by investors – that's known as Catabasis Pharmaceuticals's "short interest". This figure is 0.1% up from 577,619 last month.

There are a few different ways that this level of interest in shorting Catabasis Pharmaceuticals shares can be evaluated.

Catabasis Pharmaceuticals's "short interest ratio" (SIR)

Catabasis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Catabasis Pharmaceuticals shares currently shorted divided by the average quantity of Catabasis Pharmaceuticals shares traded daily (recently around 664716.09195402). Catabasis Pharmaceuticals's SIR currently stands at 0.87. In other words for every 100,000 Catabasis Pharmaceuticals shares traded daily on the market, roughly 870 shares are currently held short.

However Catabasis Pharmaceuticals's short interest can also be evaluated against the total number of Catabasis Pharmaceuticals shares, or, against the total number of tradable Catabasis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Catabasis Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Catabasis Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0132% of the tradable shares (for every 100,000 tradable Catabasis Pharmaceuticals shares, roughly 13 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Catabasis Pharmaceuticals.

Find out more about how you can short Catabasis Pharmaceuticals stock.

Catabasis Pharmaceuticals share dividends

We're not expecting Catabasis Pharmaceuticals to pay a dividend over the next 12 months.

Have Catabasis Pharmaceuticals's shares ever split?

Catabasis Pharmaceuticals's shares were split on a 1:6 basis on 19 August 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Catabasis Pharmaceuticals shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Catabasis Pharmaceuticals shares which in turn could have impacted Catabasis Pharmaceuticals's share price.

Catabasis Pharmaceuticals share price volatility

Over the last 12 months, Catabasis Pharmaceuticals's shares have ranged in value from as little as $6.31 up to $38.7558. A popular way to gauge a stock's volatility is its "beta".

CATB.US volatility(beta: 1.66)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catabasis Pharmaceuticals's is 1.6632. This would suggest that Catabasis Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Catabasis Pharmaceuticals overview

Catabasis Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts. .

Catabasis Pharmaceuticals in the news

There are no recent company news

Frequently asked questions

What percentage of Catabasis Pharmaceuticals is owned by insiders or institutions?
Currently 0.034% of Catabasis Pharmaceuticals shares are held by insiders and 55.084% by institutions.
How many people work for Catabasis Pharmaceuticals?
Latest data suggests 20 work at Catabasis Pharmaceuticals.
When does the fiscal year end for Catabasis Pharmaceuticals?
Catabasis Pharmaceuticals's fiscal year ends in December.
Where is Catabasis Pharmaceuticals based?
Catabasis Pharmaceuticals's address is: 100 High Street, Boston, MA, United States, 02110
What is Catabasis Pharmaceuticals's ISIN number?
Catabasis Pharmaceuticals's international securities identification number is: US14875P2065
What is Catabasis Pharmaceuticals's CUSIP number?
Catabasis Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 14875P107

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site